title: Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient.
abstract: An HIV-infected patient with very low atazanavir (ATV) plasma trough concentrations despite clinical signs of poor drug tolerability was described. By therapeutic drug monitoring (TDM), the authors found that the patient had an atypical ATV pharmacokinetics characterized by rapid drug absorption followed by very fast drug clearance probably attributable to his genetic background. This case underlines the importance of traditional and pharmacogenetic-based TDM for the individualization of ATV therapy in HIV-1 patients.
authors.affiliation: Unit of Clinical Pharmacology, Luigi Sacco University Hospital, Università di Milano, Milan, Italy. cattaneo.dario@hsacco.it
authors.forename: Dario
authors.initials: D
authors.lastname: Cattaneo
authors.forename: Paola
authors.initials: P
authors.lastname: Meraviglia
authors.forename: Valeria
authors.initials: V
authors.lastname: Cozzi
authors.forename: Sara
authors.initials: S
authors.lastname: Baldelli
authors.forename: Greta
authors.initials: G
authors.lastname: Milani
authors.forename: Emilio
authors.initials: E
authors.lastname: Clementi
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000069446:Atazanavir Sulfate; D016903:Drug Monitoring; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D010597:Pharmacogenetics; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate